Skye Bioscience's Losses Mount Amid R&D Surge, Nimacimab Fails Phase 2a

TL;DR

**SKYE is burning cash fast with a failed trial, making it a high-risk bet that needs more capital ASAP or it's toast.**

AI Summary

Skye Bioscience, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $41,482,851, a substantial rise from $16,820,644 in the same period of 2024. This 146.6% increase was primarily driven by a surge in research and development (R&D) expenses, which more than doubled to $30,892,454 from $10,908,538. The company's cash and cash equivalents plummeted from $68,415,741 at December 31, 2024, to $18,441,079 by September 30, 2025, with total current assets decreasing from $70,827,247 to $39,924,794. This decline was partially offset by the purchase of $16,871,229 in short-term investments. The company's accumulated deficit grew to $172,432,523, up from $130,949,672 at year-end 2024. A critical development was the failure of its Phase 2a study for nimacimab to meet its primary endpoint in October 2025, leading to a cost reduction plan. Despite raising $83,556,563 from PIPE financings in early 2024, the company acknowledges the need for additional funding to support future clinical studies for nimacimab.

Why It Matters

Skye Bioscience's substantial increase in net loss and R&D expenses, coupled with the failure of its nimacimab Phase 2a study, signals significant challenges for investors. The company's dwindling cash reserves, from $68.4 million to $18.4 million in nine months, highlight a precarious liquidity position, especially in a competitive biotech landscape where clinical trial success is paramount. This setback could impact employee morale and future hiring, while customers awaiting new obesity treatments will see delays. The broader market may view this as another example of the high-risk nature of early-stage biotech investments, potentially affecting valuations for similar clinical-stage companies.

Risk Assessment

Risk Level: high — Skye Bioscience faces a high risk level due to its significant operating losses of $43,268,021 for the nine months ended September 30, 2025, and a net loss of $41,482,851. The company's cash and cash equivalents decreased by over 73% from $68,415,741 at December 31, 2024, to $18,441,079 at September 30, 2025, and it explicitly states that additional funding will be required for future clinical studies, especially after nimacimab failed its Phase 2a primary endpoint.

Analyst Insight

Investors should exercise extreme caution and consider divesting, given the significant cash burn, increased losses, and the critical failure of the nimacimab Phase 2a study. The company's need for additional funding, coupled with a cost reduction plan, indicates a challenging path forward and high dilution risk for existing shareholders.

Financial Highlights

debt To Equity

0.26

revenue

$0

operating Margin

N/A

total Assets

$ 41,324,289

total Debt

$ 8,488,104

net Income

$ -41,477,451

eps

N/A

gross Margin

N/A

cash Position

$ 18,441,079

revenue Growth

N/A

Key Numbers

• $41.5M — Net Loss (for the nine months ended September 30, 2025, up 146.6% from $16.8M in 2024)
• $30.9M — Research and Development Expenses (for the nine months ended September 30, 2025, more than double the $10.9M in 2024)
• $18.4M — Cash and Cash Equivalents (as of September 30, 2025, a decrease from $68.4M at December 31, 2024)
• $172.4M — Accumulated Deficit (as of September 30, 2025, indicating significant historical losses)
• $83.6M — Net Proceeds from PIPE Financings (raised in January and March 2024)
• $2.05M — Estimated Legal Contingency (as of September 30, 2025, related to a former employee lawsuit)
• 32,057,461 — Shares Outstanding (as of November 7, 2025)

Key Players & Entities

• Skye Bioscience, Inc. (company) — registrant
• nimacimab (product) — product candidate for obesity
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Global Market (market) — exchange where common stock is registered
• Private Securities Litigation Reform Act of 1995 (law) — governs forward-looking statements
• FASB (regulator) — Financial Accounting Standards Board
• Cunning Lawsuit (legal_case) — pending litigation matter
• Bloomberg (company) — financial news organization

FAQ

Risk Factors

• Significant increase in net loss and cash burn [high — financial]: The company reported a net loss of $41.5 million for the nine months ended September 30, 2025, a 146.6% increase from $16.8 million in the prior year. This was driven by a more than doubling of R&D expenses to $30.9 million. Cash and cash equivalents decreased from $68.4 million to $18.4 million, indicating a rapid burn rate.
• Need for additional financing [high — financial]: Despite raising $83.6 million from PIPE financings in early 2024, the company acknowledges the need for additional funding to support future clinical studies for nimacimab. The substantial increase in net loss and decrease in cash position highlight the urgency of securing further capital.
• Failure of Phase 2a study for nimacimab [high — regulatory]: The Phase 2a study for nimacimab failed to meet its primary endpoint in October 2025. This critical development directly impacts the company's lead drug candidate and necessitates a cost reduction plan, raising questions about the future viability of this program.
• Cost reduction plan implementation [medium — operational]: Following the failure of the nimacimab Phase 2a study, the company has initiated a cost reduction plan. The effectiveness and scope of this plan in mitigating financial pressures and realigning resources are yet to be determined.
• Estimated legal contingency [low — legal]: The company has an estimated legal contingency of $2.05 million as of September 30, 2025, related to a former employee lawsuit. While this is a relatively small amount compared to overall expenses, any adverse outcome could lead to additional financial strain.
• Growing accumulated deficit [medium — financial]: The accumulated deficit increased to $172.4 million as of September 30, 2025, from $130.9 million at the end of 2024. This signifies substantial historical unprofitability and a long road to potential profitability.

Industry Context

Skye Bioscience operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often hinges on the efficacy and safety of drug candidates, as demonstrated by the critical impact of the nimacimab Phase 2a study results.

Regulatory Implications

The biotechnology industry is heavily regulated by bodies like the FDA. Failure to meet study endpoints, as seen with nimacimab, can lead to significant delays, increased costs, or outright termination of development programs. Companies must navigate complex approval pathways and adhere to strict manufacturing and safety standards.

What Investors Should Do

1. Monitor future funding announcements closely.
2. Evaluate the impact of the nimacimab Phase 2a failure on the company's strategy.
3. Assess the company's ability to manage its cash burn rate.

Key Dates

• 2024-01-01: PIPE financings — Raised $83.6 million, providing capital for operations and R&D, but this capital is being rapidly depleted.
• 2025-09-30: End of Nine Months Reporting Period — Reported a significant increase in net loss ($41.5M) and a sharp decline in cash ($18.4M), with R&D expenses more than doubling.
• 2025-10-01: Phase 2a study for nimacimab failed to meet primary endpoint — A critical setback for the company's lead drug candidate, leading to a cost reduction plan and raising concerns about future development.

Glossary

Accumulated deficit

The total net losses of a company since its inception, minus any net profits. It represents the cumulative losses that have not been offset by profits. (Indicates the company's long-term unprofitability, with the deficit growing to $172.4 million.)

Cash burn rate

The rate at which a company spends its available cash to finance overhead and operations when it is not generating sufficient revenue to cover its expenses. (The company's cash and cash equivalents have significantly decreased from $68.4 million to $18.4 million, highlighting a high cash burn rate, especially due to increased R&D.)

PIPE Financing

Private Investment in Public Equity. A transaction where an institutional investor buys stock directly from a publicly traded company at a discount. (Skye Bioscience raised $83.6 million through PIPE financings in early 2024, which is crucial for funding its operations and clinical trials.)

Net loss

The total expenses of a company exceed its total revenues over a specific period. (The company's net loss has substantially increased by 146.6% to $41.5 million for the nine months ended September 30, 2025.)

Research and development (R&D) expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (These expenses more than doubled to $30.9 million for the nine months ended September 30, 2025, significantly contributing to the increased net loss.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Skye Bioscience has experienced a dramatic increase in its net loss, up 146.6% to $41.5 million, primarily due to a more than doubling of R&D expenses to $30.9 million. This surge in spending, coupled with the failure of its Phase 2a study for nimacimab, has led to a significant depletion of cash reserves, which fell from $68.4 million to $18.4 million. The company's accumulated deficit has also grown substantially, underscoring its ongoing unprofitability.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 SKYE Nasdaq Global Market Indicate by

Filing Documents

• skye-20250930.htm (10-Q) — 757KB
• skye-20250930xex311xsectio.htm (EX-31.1) — 10KB
• skye-20250930xex312xsectio.htm (EX-31.2) — 11KB
• skye-20250930xex321xsectio.htm (EX-32.1) — 5KB
• skye-20250930xex322xsectio.htm (EX-32.2) — 5KB
• 0001628280-25-051031.txt ( ) — 4442KB
• skye-20250930.xsd (EX-101.SCH) — 30KB
• skye-20250930_cal.xml (EX-101.CAL) — 48KB
• skye-20250930_def.xml (EX-101.DEF) — 149KB
• skye-20250930_lab.xml (EX-101.LAB) — 479KB
• skye-20250930_pre.xml (EX-101.PRE) — 311KB
• skye-20250930_htm.xml (XML) — 482KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements: 4 Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 4 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 6 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 7 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 8 Notes to the Unaudited Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 27 Item 1A.

Risk Factors

Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27 Item 3. Defaults Upon Senior Securities 27 Item 4. Mine Safety Disclosures 27 Item 5. Other Information 27 Item 6. Exhibits 28 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this Quarterly Report are forward-looking statements, including without limitation, statements regarding: the period over which we estimate our existing cash, cash equivalents and short-term investments will be sufficient to fund our future operating expenses and capital expenditure requirements, including that our existing cash, cash equivalent, and marketable securities will be sufficient to fund our obligations for at least 12 months after the issuance of the condensed consolidated financial statements included in this report; the timing, progress and results of preclinical studies and clinical studies for nimacimab, including any future studies or plans to evaluate combinations of nimacimab and incretin-based therapies; the timing, scope and likelihood of regulatory filings and approvals; expectations regarding the size, scope and design of future clinical studies; our manufacturing, commercialization, and marketing plans and strategies; our expectations regarding the approval and use of our product candidates; our competitive position and the development and impact of competing therapies that are or may become available; the rate and degree of market acceptance and clinical utility of product candidates we may develop; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our future financial performance; the impact of laws and regulations; our ability to raise capital to fund operations; stat

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 4 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 18,441,079 $ 68,415,741 Short-term investments 16,871,229 — Prepaid expenses 3,712,311 201,962 Other current assets 900,175 2,209,544 Total current assets 39,924,794 70,827,247 Property and equipment, net 1,033,965 1,432,752 Operating lease right-of-use asset 311,620 449,864 Other assets 53,910 53,910 Total assets $ 41,324,289 $ 72,763,773 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 2,825,005 $ 569,252 Accrued payroll liabilities 920,774 1,114,255 Other current liabilities 2,366,123 654,201 Estimate for accrued legal contingencies and related expenses 2,054,357 1,818,751 Operating lease liability, current portion 201,638 182,428 Total current liabilities 8,367,897 4,338,887 Non-current liabilities Operating lease liability, net of current portion 120,207 273,162 Total liabilities 8,488,104 4,612,049 Commitments and contingencies (Note 7) Stockholders' equity Preferred stock, $ 0.001 par value; 200,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value; 100,000,000 shares authorized at September 30, 2025 and December 31, 2024; 30,989,046 and 30,974,559 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 30,989 30,975 Additional paid-in-capital 205,237,719 199,070,421 Accumulated deficit ( 172,432,523 ) ( 130,949,672 ) Total stockholders' equity 32,836,185 68,151,724 Total liabilities and stockholders' equity $ 41,324,289 $ 72,763,773 See accompanying notes to the unaudited condensed consolidated financial statements. 5 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Fo

View Full Filing

View this 10-Q filing on SEC EDGAR